KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Total Debt (2019 - 2026)

Evolent Health has reported Total Debt over the past 7 years, most recently at $970.5 million for Q4 2025.

  • For Q4 2025, Total Debt rose 46.61% year-over-year to $970.5 million; the TTM value through Dec 2025 reached $970.5 million, up 46.61%, while the annual FY2025 figure was $970.5 million, 46.61% up from the prior year.
  • Total Debt for Q4 2025 was $970.5 million at Evolent Health, down from $1.1 billion in the prior quarter.
  • Over five years, Total Debt peaked at $1.1 billion in Q3 2025 and troughed at $215.7 million in Q4 2021.
  • A 5-year average of $544.9 million and a median of $598.3 million in 2024 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: decreased 25.6% in 2021 and later skyrocketed 123.74% in 2023.
  • Year by year, Total Debt stood at $215.7 million in 2021, then surged by 91.48% to $413.0 million in 2022, then surged by 44.57% to $597.0 million in 2023, then grew by 10.88% to $662.0 million in 2024, then soared by 46.61% to $970.5 million in 2025.
  • Business Quant data shows Total Debt for EVH at $970.5 million in Q4 2025, $1.1 billion in Q3 2025, and $820.6 million in Q2 2025.